Questions remain about total program cost, sustainability, patients ability to afford the additional monthly cost (will foundations be able and willing to provide additional funding for eligible patients), and whether this policy workaround will lead to permanent Medicare expansion for GLP-1 coverage, despite significant projected budget impact
Adding glucagon activation to the GLP-1/GIP combination is what pushes retatrutide to the 24% to 29% weight loss range
Acetyl L-Carnitine does and that distinction matters significantly for cognitive support.*
They are also available in the more traditional tablets and capsules
Tirzepatide, a dual GIP and GLP-1 receptor agonist, showed even greater weight reduction in clinical trials, with some participants losing 20% or more of body weight
Their once-a-week administration makes them more convenient and easier to use compared to taking a daily pill or shot of insulin